Trial
NCT04544267
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi Pasteur, a Sanofi Company
Collaborators
—
Condition
Influenza
Intervention
Quadrivalent influenza vaccine, high-dose
Why stopped
The study was interrupted due to COVID-19 pandemic and terminated due to new changes to the recommendations for flu vaccines
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-24